Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Northeast · Pennsylvania
Local context for Wegovy, Ozempic, Mounjaro, and Zepbound in Philadelphia (1,550,000 residents, 6,240,000 metro). Penn Medicine and Jefferson run multidisciplinary obesity-medicine programs; PA Medical Assistance generally covers GLP-1s for T2D with prior auth.
Availability and prices vary by pharmacy and date. We do not maintain real-time per-pharmacy stock data. Confirm with pharmacies directly.
Wegovy
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for chronic weight management in adults and adolescents.
Wegovy in Philadelphia →
Ozempic
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for adults with type 2 diabetes.
Ozempic in Philadelphia →
Mounjaro
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for adults with type 2 diabetes.
Mounjaro in Philadelphia →
Zepbound
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for chronic weight management and obstructive sleep apnea.
Zepbound in Philadelphia →
Philadelphia is a northeast-region city with a population of 1,550,000 (6,240,000 in the broader metropolitan area). Pennsylvania expanded Medicaid under the Affordable Care Act, which means low-income adults can typically qualify for GLP-1 coverage for type 2 diabetes if the state Medicaid program lists the drug.
Statewide, notable health systems include UPMC, Penn Medicine, Children's Hospital of Philadelphia.
Pennsylvania's Medicaid program is Pennsylvania Medical Assistance (HealthChoices). Coverage rules for GLP-1 medications vary by drug and indication; see our pricing by state map and payer-coverage guides for details.
Cities of similar size with comparable healthcare markets.